1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Medical specialties
NeoCore Technology Co., Ltd

NeoCore Technology Co., Ltd

TTPEX:4131
30.00
TWD
-0.50
(-1.64%)
-0.19EPS
1.33BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
4.07
1.76
1.49
1.1
0.81
3.4
5.5
4.91
4.68
4.68
1.87
1.58
- -
7.09
Basic EPS, GAAP
-3
-1.44
-1.15
-1.85
-1.42
-1.38
-0.62
-1.43
-0.91
-1.48
-1.87
-1.23
- -
-0.19
Free Cash Flow per Basic Share
- -
-8.14
3.51
-1.57
2.47
-1.53
-0.25
-1.47
-0.9
-0.18
-2.18
-1.79
- -
-2.54
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
10.85
12.24
11.09
9.22
7.8
8.52
7.9
6.8
5.9
4
8.8
7.72
- -
7.19
Tangible Book Value per Share
10.15
11.37
10.26
8.73
7.36
8.21
7.62
6.56
5.69
3.83
8.73
7.67
- -
5.12
Basic Weighted Avg Shares
15
15
15
15
15
18
19
19
19
19
35
39
40
37
Sales/Revenue/Turnover
61
27
22
17
12
62
104
93
89
89
65
62
- -
265
Operating Margin (%)
-89.69
-100.61
-86.84
-137.37
-173.86
-41.51
-17.91
-35.17
-31.81
-45.26
-131.18
-123.22
- -
-11.97
Depreciation Expense
9
7
6
4
4
4
8
7
7
7
8
8
- -
35
Net Income, GAAP
-45
-22
-17
-28
-21
-25
-12
-27
-17
-28
-65
-48
- -
-7
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-73.66
-81.72
-77.3
-168.29
-174.59
-40.57
-11.36
-29.03
-19.34
-31.71
-99.87
-78.21
- -
-2.71
Working Capital
89
73
63
45
28
78
66
63
42
- -
261
202
- -
30
LT Debt
- -
- -
- -
- -
- -
- -
1
- -
34
32
34
22
- -
37
Total Equity
206
184
167
139
118
162
150
141
117
81
351
305
- -
307
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-19.75
-11.11
-9.88
-18.19
-16.66
-17.94
-7.61
-19.4
-14.25
-30.02
-30.52
-14.75
- -
-2.47

Capital Structure

TWD

•

in mil. unless spec.
Sep'25
Mar'26
Jun'26
ST Debt
115
133
150
LT Borrowings
- -
- -
- -
LT Finance Leases
43
39
37
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
40
40
40
Market Capitalization
1,304
1,440
1,333

Working Capital

TWD

•

in mil. unless spec.
Sep'25
Mar'26
Jun'26
Total Current Assets
271
232
253
Cash, Cash Equivalents & STI
124
65
76
Accounts Receivable, Net
25
37
23
Inventories
108
107
116
Total Current Liabilities
188
186
223
Payables & Accruals
- -
- -
- -
ST Debt
115
133
150
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
16
18
16
12
62
2025
70
54
55
- -
- -
2026
60
96
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.4
-0.39
-0.36
-0.09
-1.23
2025
-0.31
0.31
-0.42
- -
- -
2026
-0.05
-0.02
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Wen Sheng Ji
Full Time Employees
44
Sector
Health technology
Industry
Medical specialties
Address
No. 395, Linsen Road Tainan TQ Taiwan 701
IPO Date
Mar 12, 2003
Website
bio-drchip.com.tw
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
NeoCore Technology Co., Ltd. NeoCore Technology Co., Ltd. (4131.TWO) designs, manufactures, and sells biochips and rapid nucleic acid hybridization devices for applications in food safety testing, pathogen detection, and clinical diagnostics. The company's core products include nucleic acid extraction kits, polymerase chain reaction kits, enterovirus identification chips, dairy microbial detection chips, Newcastle disease virus and poultry influenza virus nucleic acid chip testing reagent kits, high-risk human papillomavirus detection chip reagents, and human papillomavirus genotyping test kits for cervical cancer screening; it also provides related rapid hybridization instruments and microfluidic systems to enable high-sensitivity molecular testing. NeoCore Technology operates primarily in Taiwan with manufacturing in Zhunan Science Park, Miaoli County, and serves customers including academic institutions, medical organizations, food manufacturers, and partners in Europe, Asia, and Australia. Founded in 1998 as Dr. Chip Biotechnology Incorporation with headquarters in Tainan City, Taiwan, the company holds ISO9001 and ISO13485 certifications, a GMP license acquired in 2022, and medical equipment registrations from Taiwan's Ministry of Health and Welfare. In 2023, it reorganized and renamed to NeoCore Technology Co., Ltd., reflecting a strategic shift toward diversified biotechnology operations while maintaining focus on biochip innovation; recent advancements include machine upgrades, automation integration, and expanded clinical testing platforms to enhance timeliness and accuracy in early detection.